Adefovir (CAS 106941-25-7): Identity, Dipivoxil Distinction and Sourcing

Adefovir (CAS 106941-25-7; also known as PMEA) is a chemical substance listed in PubChem, CID 60172, with molecular formula C₈H₁₂N₅O₄P. Correctly identifying the substance is essential when discussing pharmaceutical research or procurement.

Adefovir and adefovir dipivoxil are distinct

The prescription product HEPSERA contains adefovir dipivoxil, a prodrug of adefovir. The official HEPSERA prescribing information on DailyMed identifies that finished tablet product and its active ingredient.

A label for adefovir dipivoxil tablets is not a dosing instruction for adefovir raw material. A raw-material listing cannot be substituted for a prescribed finished medicine. The compound, its prodrug and the formulated product must be distinguished in specifications, analytical methods and regulatory documents.

Identity checklist

Interpreting medicine references

Medicine labeling describes the use, precautions and limitations of a particular approved product. It does not establish that every material sold under a related chemical name has the same quality, bioavailability, approval or clinical suitability. Product choice and treatment decisions require qualified clinical assessment and current prescribing information.

This page does not recommend a medicine or a dose. Anyone already receiving treatment should discuss changes and questions with the prescribing healthcare professional.

Reviewing the Longchang catalog record

The Longchang adefovir product record contains historical catalog specification fields. Confirm the current limits and test procedures before relying on them for an order. A listed assay value does not establish compliance with every pharmacopoeia or authorize use in a finished medicine.

When reviewing impurity results, compare the method, reporting threshold, reference standards and calculation basis as well as the numerical limit. Ensure that the COA identifies the actual lot and agrees with the specification named in the quotation.

Preparing a procurement request

• State the full chemical name and identifier, including whether adefovir or adefovir dipivoxil is intended.
• Provide your required standard and the analytical or quality documents needed for review.
• Specify sample and commercial quantities, packaging requirements and destination.
• Ask for confirmation of availability, document revisions and any applicable supply restrictions.

Handling and regulatory boundary

Use the current SDS and workplace risk assessment for handling, storage and disposal. Raw materials and research samples must not be used for self-treatment. The Technical & Medical Disclaimer explains the distinction between chemical information, product documentation and clinical advice.

Reviewed and corrected: 10 September 2026. This revision distinguishes adefovir from adefovir dipivoxil tablets and removes patient dosing, unverified broad efficacy claims and blanket pharmacopoeial guarantees.